The Type to Treat program, hosted by the Biomedical Advanced Research and Development Authority (BARDA), aims to advance the development of endotyping technologies for patient stratification, improving therapeutic efficacy in clinical treatment. The program focuses on creating commercially sustainable stratification products that can be used in medical countermeasure (MCM) development to enhance treatment effectiveness for injuries, infections, or severe diseases in specific populations.

This opportunity is for companies or teams developing patient stratification platforms and technologies that can predict treatment responses. The goal is to transition from traditional “Test to Treat” approaches to more personalized interventions based on prognostication, ensuring the highest overall therapeutic efficacy.

The application deadline is May 12, 2025, at 12:00 PM EST. To begin your application or learn more about the opportunity, click here.